STARmed has taken RFA to the next level by introducing ELRATM, Endo Luminal Radiofrequency Ablation catheter, to help patients with hepatic, biliary, or pancreatic unresectable endoluminal lesions. It is a flexible RFA electrode with an automatic Temperature Sensing System, offering interventional radiologists a minimally invasive palliative care option to enhance patients’ quality of life.
5-year survival rate for cholangiocarcinoma (CCA), but varies based on the state of the cancer at diagnosis
of patients with CCA (Cholangiocarcinoma) have unresectable disease at presentation
of patients will have stent occlusion in the first 6 to 8 months.
The ELRA Electrode is an innovative RFA catheter inserted over the wire (OTW), to ablate tissues in the hepatopancreatobiliary ducts. It is designed to effectively clear obstructions and tumor growth through a percutaneous approach.
Under fluoroscopic guidance, the ELRA electrode is advanced into the targeted segment of the duct to achieve ablations.4 With 4 varying exposure lengths, ELRA completes ablations for varying lengths of stricture safely and effectively.5
According to multiple prospective single or multicenter studies, temperature-controlled intraductal RFA using the ELRA platform appeared feasible and safe with acceptable biliary patency. Temperature-controlled RFA avoids excessive heating and significant vessel or bile duct injury. 6,7
As RFA produces promising results in patients with a variety of gastrointestinal and hepatopancreatobiliary pathologies, physicians have been exploring different applications of ELRA to enhance palliative care for patients.
The ELRA Electrode is a radiofrequency (RF) catheter which provides bipolar energy to perform partial or complete ablation of tissue in the pancreatic and biliary tracts